Understanding the Most Common Side Effects of Ozempic Injection

Last reviewed: June 24, 2026

Last updated: June 24, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The most common adverse reactions to Ozempic injection are gastrointestinal. Section 6.1 of the Ozempic prescribing information states that the most common adverse reactions reported in at least 5% of patients treated with Ozempic are nausea, vomiting, diarrhea, abdominal pain, and constipation. Those five account for the overwhelming majority of what people experience, they are dose-related, and the label reports that most of them clustered in a specific window of treatment. Understanding which effects are common and expected — and which are the rarer ones the label warns about — is the difference between an informed conversation with a prescriber and an anxious one.

What the Trial Data Actually Show

The label's placebo-controlled trial table gives incidence figures at the two studied maintenance strengths against placebo. Nausea occurred in 15.8% of patients at 0.5 mg and 20.3% at 1 mg, versus 6.1% with placebo. Vomiting occurred in 5% and 9.2%, versus 2.3%. Diarrhea occurred in 8.5% and 8.8%, versus 1.9%. Abdominal pain occurred in 7.3% and 5.7%, versus 4.6%. Constipation occurred in 5% and 3.1%, versus 1.5%.

Two things stand out. The placebo columns are not zero — a meaningful fraction of people report these symptoms on no active drug at all, which is worth remembering before attributing every symptom to a medication. And the gradient with strength is real for nausea and vomiting, which is the clinical basis for the label's stepwise approach to increasing strength rather than starting at a maintenance level.

Timing: Most of It Happens During Escalation

The label is specific about when these reactions occur: the majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. That is the period when circulating drug concentration is rising, and it is why the first weeks at any new strength are the ones prescribers ask about most closely.

The corresponding discontinuation figures give a sense of scale. More patients receiving Ozempic 0.5 mg (3.1%) and 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%). So while roughly one in five people reported nausea at the higher strength, only a small minority stopped therapy because of gastrointestinal effects.

Why the Gut Is Where This Shows Up

Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1, and it acts by selectively binding to and activating the GLP-1 receptor. Among the mechanisms the label describes for its effect on blood glucose is a minor delay in gastric emptying in the early postprandial phase. GLP-1 receptors are distributed in tissues involved in digestion and appetite regulation, so gastrointestinal effects are not an off-target surprise — they are downstream of the same signalling that produces the intended effect.

This also explains why these effects tend to be most pronounced when exposure changes rather than at any fixed level. The system adapts. What it adapts to is stability, which is part of why the label emphasizes consistent once-weekly administration.

The Warnings That Are Not Common but Are Serious

Ozempic carries a boxed warning for risk of thyroid C-cell tumors. In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures; the label states it is unknown whether Ozempic causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans, because the human relevance of the rodent finding has not been determined. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2.

Beyond the boxed warning, section 5 covers acute pancreatitis, diabetic retinopathy complications, hypoglycemia with concomitant use of insulin secretagogues or insulin, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, hypersensitivity reactions, acute gallbladder disease, and pulmonary aspiration during general anesthesia or deep sedation. Section 5.4 separately warns never to share a pen between patients, even with a changed needle.

How the Common and the Serious Connect

Acute kidney injury due to volume depletion is the clearest example of the link. Persistent vomiting or diarrhea causes fluid loss, and fluid loss is the pathway to the renal warning. That is why a prescriber's response to "I have been vomiting for three days" is different from their response to "I felt queasy on Tuesday" — the concern is not the nausea itself but where sustained gastrointestinal losses lead.

The same logic applies to hypoglycemia. Ozempic on its own is not the primary driver, but combined with insulin or an insulin secretagogue the label flags the risk explicitly. Anything that changes food intake — which gastrointestinal side effects certainly do — interacts with that combination. These are prescriber decisions, not self-management decisions.

What to Report and When

Severe or persistent abdominal pain, particularly radiating to the back and with or without vomiting, is the presentation the pancreatitis warning is written around. Vision changes matter because of the retinopathy warning. Signs of a hypersensitivity reaction, a neck mass, difficulty swallowing, shortness of breath, or persistent hoarseness are all in the label's counselling points.

One practical item is easy to miss: because of the pulmonary aspiration warning, anyone scheduled for a procedure involving general anesthesia or deep sedation should tell the surgical and anesthesia teams they are taking a GLP-1 medication, well in advance. Any strategy for managing common side effects belongs with your prescriber, who can weigh it against your full clinical picture.

Compounded Semaglutide and the Side-Effect Question

Compounded semaglutide contains the same active molecule as the FDA-approved semaglutide products, including the injection and the oral semaglutide tablets, so the pharmacology behind these effects is the same. What differs is regulatory status: compounded preparations are not FDA-approved finished products, and the FDA does not review them for safety, effectiveness, or quality before marketing. They are prepared by a licensed pharmacy pursuant to a prescription for an individual patient.

Because a compounded preparation has no FDA-approved label of its own, the adverse reaction data above come from the branded product's trials. Discussing what to expect, and what to report, is a conversation for the prescriber who wrote the prescription and the pharmacy that filled it.

Putting the Numbers in Perspective

Incidence figures describe populations, not individuals. A 20.3% nausea rate at the higher studied strength means roughly four in five participants did not report nausea, and the 6.1% placebo rate means some of what was reported would have occurred without the drug. Neither number tells any particular person what they will experience.

The trial data also come from a defined setting: adults with type 2 diabetes, in monitored studies, at studied strengths, over defined periods. Real-world use varies on all of those axes. That is an argument for tracking your own experience — what, when, how severe, and at what point in treatment — and bringing that record to your prescriber, rather than trying to match yourself against a table.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

What are the most common side effects of Ozempic?

Section 6.1 of the Ozempic prescribing information states that the most common adverse reactions reported in at least 5% of patients are nausea, vomiting, diarrhea, abdominal pain, and constipation. In the placebo-controlled trial table, nausea occurred in 15.8% of patients at 0.5 mg and 20.3% at 1 mg versus 6.1% with placebo, and vomiting in 5% and 9.2% versus 2.3%.

When do gastrointestinal effects tend to occur?

The label states that the majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation — the period when circulating drug concentration is rising. Discontinuation because of gastrointestinal adverse reactions was uncommon overall: 3.1% at 0.5 mg and 3.8% at 1 mg, compared with 0.4% on placebo. That is why prescribers ask closely about the first weeks at any new strength.

Why does semaglutide affect the digestive system?

Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1 that selectively binds to and activates the GLP-1 receptor. Among the mechanisms the label describes for its glucose-lowering effect is a minor delay in gastric emptying in the early postprandial phase. GLP-1 receptors sit in tissues involved in digestion and appetite, so these effects are downstream of the intended signalling.

What serious risks does the label warn about?

Ozempic carries a boxed warning for risk of thyroid C-cell tumors, based on dose-dependent and treatment-duration-dependent tumors in rodents; human relevance has not been determined. It is contraindicated with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Section 5 also covers pancreatitis, gallbladder disease, kidney injury, hypoglycemia, and retinopathy complications.

What should be reported to a prescriber?

Severe or persistent abdominal pain, with or without vomiting, is the presentation the pancreatitis warning addresses. Vision changes matter because of the diabetic retinopathy warning, and a neck mass, difficulty swallowing, shortness of breath, or persistent hoarseness are label counselling points. Because of the pulmonary aspiration warning, tell any anesthesia team well in advance that you take a GLP-1 medication.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.